Abstracto

Hepatocyte growth factor shows benefits for patients with chronic renal failure induced type 2 diabetes

Gan Yu, Zhou Hui Hua, Zhang Li, Li Tong Wei

Chronic renal failure patients receiving haemodialysis and continuous ambulatory peritoneal dialysis often encounter inflammation troubles during long-period treatment. Patients with type 2 diabetes induce different degree chronic renal failure and represent low quality of life. Type 2 diabetes may be one of the most important arch-criminal factors that aggravate syndrome and renal insufficiency. These impairments of kidney’s function may lead to chronic renal failure though disqualify of cellular activities. Hepatocyte Growth Factor (HGF) is one of the most extensive biological activity factors and presents multifunctional anti-fibrosis factor that plays a critical role in the progression of chronic renal failure. The purpose of this study was to investigate whether HGF treatment could decrease inflammation and improve chronic renal failure. Clinical investigations were performed in 138 (75 men and 63 women) chronic renal failure patients induced by type 2 diabetes with 98 healthy volunteers (51 men and 41 women) as control. Our experimental data showed that serum level of HGF and IL-6 were decreased and correlated with age and sex in patients with chronic renal failure induced by type 2 diabetes (r=0.864, r=0.743, respectively). Serum levels of IL-1, MCP-1 and TNF-α were increased compared between patients with severe renal failure and healthy volunteers (**P<0.01). HGF injection (MTD dose) improved the inflammatory factor expression levels for patients with chronic renal failure compared to placebo group. The most common treatment-emergence adverse events were hypertension and proteinuria. Taken together, level of HGF in serum was correlated with inflammation in chronic renal failure patients induced by type 2 diabetes, which presented beneficial outcomes through improvement of inflammatory factor expression in clinical.